ClinicalTrials.gg
RecruitingNCT07511413GALENOS 1Updated Apr 6, 2026

GALENOS 1 in Head and Neck, Lung, and Rectal Cancer Patients

An observational study in Head and Neck Squamous Cell Carcinoma, Locally Advanced Rectal Cancer and Lung Cancer, sponsored by Fondazione del Piemonte per l'Oncologia. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-06.

Sponsored by Fondazione del Piemonte per l'Oncologia · Observational

How we know

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
110
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 129 studies in Squamous Cell Carcinoma of Head and Neck with a site in Italy — 44 open to participants now, 62 under way, 13 of them phase 3. Squamous Cell Carcinoma of Head and Neck · Italy.

Planned enrollment
13th of 20
110 · median 135
Started
2024
with 15 others
Observational
20 of 129
16 open now
Primary completion
2027-08
later than 33 of 61 live
Registered
125th of 129
by date
Lead sponsor
3 of 129
Fondazione del Piemonte per l'Oncologia

Among the 129 studies in Squamous Cell Carcinoma of Head and Neck with a site in Italy, this one is the 13th largest by planned enrollment of the 20 observational ones that give a count, is one of 16 that started in 2024, is one of 20 observational ones, reaches primary completion later than 33 of the 61 other live ones, and was the 125th registered.

Squamous Cell Carcinoma of Head and Neck

2,023 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

44 of the 129 studies in Squamous Cell Carcinoma of Head and Neck with a site in Italy are open now. Recruiting first, the newest first:

38 more — sign in →

All 44 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 434 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 310 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 129 studies in Squamous Cell Carcinoma of Head and Neck with a site in Italy, or all of them as a file.
02

Study summary

GALENOS 1 is a prospective observational study designed to explore longitudinal changes in nutritional status and body composition in patients with head and neck squamous cell carcinoma, locally advanced rectal cancer, and lung cancer undergoing standard antineoplastic treatments. The study is the preparatory observational component of the FOR-GALE PREVENTION project, which aims to support the future development of a galenic immunonutrition dietary supplement intended to reduce adverse events and improve treatment compliance

Read the detailed description

This single-center prospective observational cohort study will enroll adult patients with pathologically confirmed head and neck squamous cell carcinoma, locally advanced rectal cancer, or lung cancer who are candidates for standard antineoplastic treatment according to routine clinical practice. The study will longitudinally assess nutritional intake, anthropometric and body composition parameters, muscle function, circulating cytokines, quality of life, treatment-related toxicity, and treatment tolerance. Study procedures include dietary visits, 3-day food records, nutritional screening, bioimpedance analysis, handgrip testing, cytokine sampling, quality-of-life questionnaires, and collection of treatment adherence/tolerance data at predefined time points from baseline through follow-up. The study aims to generate observational data to inform future immunonutritional interventional studies

03

Conditions studied

  • Head and Neck Squamous Cell Carcinoma
  • Locally Advanced Rectal Cancer
  • Lung Cancer

Keywords

  • Head and Neck Squamous Cell Carcinoma
  • Lung Cancer
  • Locally Advanced Rectal Cancer
  • Nutritional Status
  • Body Composition
  • Skeletal Muscle Mass
  • Sarcopenia
  • Bioimpedance Analysis
  • Handgrip Strength
  • Cytokines
  • Quality of Life
  • Treatment Toxicity
  • Treatment Tolerance
  • Immunonutrition
  • Supportive Care
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients with histologically or cytologically documented head and neck squamous cell carcinoma, locally advanced rectal cancer, or lung cancer who are candidates for standard antineoplastic treatment at Fondazione del Piemonte per l'Oncologia - IRCCS Candiolo and meet protocol eligibility criteria

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written provided before study procedures
  • Male or female participants aged 18 years or older
  • Histological or cytological documentation of head and neck squamous cell carcinoma, locally advanced rectal cancer, or lung cancer
  • Candidate for standard antineoplastic treatment according to clinical practice
  • Performance Status score less than 2
  • Adequate kidney, liver, and bone marrow function
  • Ability to adhere to study visits and protocol requirements

Exclusion criteria

Exclusion Criteria:

  • Incomplete recovery from surgery before start of antineoplastic treatment
  • Other additional progressing or requiring active treatment within the previous 3 years, except localized basal cell carcinoma, localized squamous cell carcinoma of the skin, or cervical carcinoma in situ
  • Active infection requiring systemic antibiotic therapy Serious or unstable medical conditions, psychiatric disorders, or substance abuse that would interfere with study compliance
  • Receipt of any within 30 days before planned start of study therapy
  • Active cardiac pacing/pacing implants/neurostimulators/hearing systems not compatible with bioimpedance analysis
  • Edema and/or ascites interfering with body weight evaluation or bioimpedance analysis
  • Enteral or parenteral nutritional support at baseline
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
110 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Head and Neck Squamous Cell Carcinoma Cohort

    Patients with pathologically confirmed head and neck squamous cell carcinoma (oropharynx, oral cavity, hypopharynx, larynx, nasopharynx, or sinus cancer) who are candidates for curative or adjuvant chemoradiotherapy according to standard clinical practice

  • Locally Advanced Rectal Cancer Cohort

    Patients with pathologically confirmed locally advanced rectal cancer who are candidates for neoadjuvant chemoradiotherapy according to standard clinical practice

  • Lung Cancer Cohort

    Patients with pathologically or cytologically confirmed lung cancer who are candidates for curative immunotherapy with or without chemotherapy according to standard clinical practice

06

What researchers measure

Primary outcomes

  1. Daily energy intake normalized to body weight

    Average daily oral energy intake assessed using a 3-day food record and expressed as kilocalories per kilogram of body weight per day (kcal/kg/day)

    Time frame: From baseline (T0, first day of antineoplastic treatment) to end of treatment/final follow-up, assessed up to approximately 3 months

  2. Skeletal muscle mass

    Skeletal muscle mass measured by bioimpedance analysis and expressed in kilograms (kg) the protocol states that phase angle may be used as an alternative depending on the BIA software

    Time frame: From baseline (T0) to final follow-up (T4), assessed up to approximately 3 months

  3. Handgrip strength

    Maximum handgrip strength measured using a handgrip dynamometer and expressed in kilograms (kg)

    Time frame: From baseline (T0) to final follow-up (T4), assessed up to approximately 3 months

Secondary outcomes

  1. Body weight

    Body weight measured in kilograms (kg)

    Time frame: From baseline (T0) to final follow-up (T4), assessed up to approximately 3 months

  2. Participants with more than 5% body weight loss

    Number of participants with body weight loss greater than 5% from baseline

    Time frame: From baseline (T0) to final follow-up (T4), assessed up to approximately 3 months

  3. Body mass index

    Body mass index calculated as body weight in kilograms divided by height in meters squared (kg/m²)

    Time frame: From baseline (T0) to final follow-up (T4), assessed up to approximately 3 months

  4. Nutritional Risk Screening 2002 score

    Nutritional risk assessed using the Nutritional Risk Screening 2002 (NRS-2002). Total scores range from 0 to 7, with higher scores indicating greater nutritional risk and worse nutritional status

    Time frame: From baseline (T0) to final follow-up (T4), assessed up to approximately 3 months

  5. Prognostic Nutritional Index

    Prognostic Nutritional Index calculated as serum albumin + 5 × total lymphocyte count. Higher values indicate better nutritional/immunologic status

    Time frame: From baseline (T0) to final follow-up (T4), assessed up to approximately 3 months

  6. Phase angle

    Phase angle measured by bioimpedance analysis and expressed in degrees. Higher values generally indicate better cellular integrity and nutritional status

    Time frame: From baseline (T0) to final follow-up (T4), assessed up to approximately 3 months

  7. Fat-free mass

    Fat-free mass measured by bioimpedance analysis and expressed in kilograms (kg)

    Time frame: From baseline (T0) to final follow-up (T4), assessed up to approximately 3 months

  8. Body cell mass

    Body cell mass measured by bioimpedance analysis and expressed in kilograms (kg)

    Time frame: From baseline (T0) to final follow-up (T4), assessed up to approximately 3 months

  9. Fat mass

    Fat mass measured by bioimpedance analysis and expressed in kilograms (kg)

    Time frame: From baseline (T0) to final follow-up (T4), assessed up to approximately 3 months

  10. Total body water

    Total body water measured by bioimpedance analysis and expressed in liters (L)

    Time frame: From baseline (T0) to final follow-up (T4), assessed up to approximately 3 months

  11. EORTC QLQ-C30 Global Health Status / Quality of Life score

    Self-perceived quality of life assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30, version 3.0 (EORTC QLQ-C30 v3.0), Global Health Status / Quality of Life scale. Scores range from 0 to 100, with higher scores indicating better global health status and quality of life.

    Time frame: From baseline (T0) to final follow-up (T4), assessed up to approximately 3 months

  12. Change in circulating CCL2 concentration

    Plasma CCL2 concentration measured using the Simple Plex system and expressed in picograms per milliliter (pg/mL)

    Time frame: From baseline (T0) to end of antineoplastic treatment (T3), assessed up to approximately 6 to 7 weeks

  13. Change in circulating CCL4 concentration

    Plasma CCL4 concentration measured using the Simple Plex system and expressed in picograms per milliliter (pg/mL)

    Time frame: From baseline (T0) to end of antineoplastic treatment (T3), assessed up to approximately 6 to 7 weeks

  14. Change in circulating CCL22 concentration

    Plasma CCL22 concentration measured using the Simple Plex system and expressed in picograms per milliliter (pg/mL)

    Time frame: From baseline (T0) to end of antineoplastic treatment (T3), assessed up to approximately 6 to 7 weeks

  15. Change in circulating CXCL10 concentration

    Plasma CXCL10 concentration measured using the Simple Plex system and expressed in picograms per milliliter (pg/mL)

    Time frame: From baseline (T0) to end of antineoplastic treatment (T3), assessed up to approximately 6 to 7 weeks

  16. Change in circulating IL-2 concentration

    Plasma IL-2 concentration measured using the Simple Plex system and expressed in picograms per milliliter (pg/mL).

    Time frame: From baseline (T0) to end of antineoplastic treatment (T3), assessed up to approximately 6 to 7 weeks

  17. Change in circulating IL-4 concentration

    Plasma IL-4 concentration measured using the Simple Plex system and expressed in picograms per milliliter (pg/mL).

    Time frame: From baseline (T0) to end of antineoplastic treatment (T3), assessed up to approximately 6 to 7 weeks

  18. Change in circulating IL-5 concentration

    Plasma IL-5 concentration measured using the Simple Plex system and expressed in picograms per milliliter (pg/mL).

    Time frame: From baseline (T0) to end of antineoplastic treatment (T3), assessed up to approximately 6 to 7 weeks

  19. Change in circulating IL-6 concentration

    Plasma IL-6 concentration measured using the Simple Plex system and expressed in picograms per milliliter (pg/mL)

    Time frame: From baseline (T0) to end of antineoplastic treatment (T3), assessed up to approximately 6 to 7 weeks

  20. Change in circulating IL-8 concentration

    Plasma IL-8 concentration measured using the Simple Plex system and expressed in picograms per milliliter (pg/mL).

    Time frame: From baseline (T0) to end of antineoplastic treatment (T3), assessed up to approximately 6 to 7 weeks

  21. Change in circulating IL-10 concentration

    Plasma IL-10 concentration measured using the Simple Plex system and expressed in picograms per milliliter (pg/mL).

    Time frame: From baseline (T0) to end of antineoplastic treatment (T3), assessed up to approximately 6 to 7 weeks

  22. Change in circulating IL-12 concentration

    Plasma IL-12 concentration measured using the Simple Plex system and expressed in picograms per milliliter (pg/mL)

    Time frame: From baseline (T0) to end of antineoplastic treatment (T3), assessed up to approximately 6 to 7 weeks

  23. Change in circulating IL-15 concentration

    Plasma IL-15 concentration measured using the Simple Plex system and expressed in picograms per milliliter (pg/mL)

    Time frame: From baseline (T0) to end of antineoplastic treatment (T3), assessed up to approximately 6 to 7 weeks

  24. Change in circulating IL-13 concentration

    Plasma IL-13 concentration measured using the Simple Plex system and expressed in picograms per milliliter (pg/mL).

    Time frame: From baseline (T0) to end of antineoplastic treatment (T3), assessed up to approximately 6 to 7 weeks

  25. Change in circulating TNF-α concentration

    Plasma TNF-α concentration measured using the Simple Plex system and expressed in picograms per milliliter (pg/mL).

    Time frame: From baseline (T0) to end of antineoplastic treatment (T3), assessed up to approximately 6 to 7 weeks

  26. Change in circulating IFN-γ concentration

    Plasma IFN-γ concentration measured using the Simple Plex system and expressed in picograms per milliliter (pg/mL

    Time frame: From baseline (T0) to end of antineoplastic treatment (T3), assessed up to approximately 6 to 7 weeks

  27. Change in circulating VEGF concentration

    Plasma VEGF concentration measured using the Simple Plex system and expressed in picograms per milliliter (pg/mL

    Time frame: From baseline (T0) to end of antineoplastic treatment (T3), assessed up to approximately 6 to 7 weeks

  28. Change in circulating TGF-β concentration

    Plasma TGF-β concentration measured using the Simple Plex system and expressed in picograms per milliliter (pg/mL

    Time frame: From baseline (T0) to end of antineoplastic treatment (T3), assessed up to approximately 6 to 7 weeks

Other outcomes

  1. Change in C-reactive protein concentration

    C-reactive protein concentration measured in peripheral blood

    Time frame: From baseline (T0) to end of antineoplastic treatment (T3), assessed up to approximately 6 to 7 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Aug 2027, 35 months after the start.

Of 107 non-industry observational studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 77 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 132. This study's planned 35 months is below that.

Counting every sponsor, half of 117 studies reached it within 77 months; a quarter within 26 and three quarters within 132.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2026
First posted
Apr 6, 2026
StartActual
Sep 23, 2024
Primary completionEst.
Aug 30, 2027
CompletionEst.
Dec 30, 2027
Last update
Apr 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07511413
Lead sponsor
Fondazione del Piemonte per l'Oncologia
Responsible party
Sponsor
First posted
Apr 6, 2026
Start date
Sep 23, 2024
Primary completion
Aug 30, 2027 (estimated)
Completion
Dec 30, 2027 (estimated)
Last update
Apr 6, 2026

Study contacts

Valentina Casalone, MD
Contact
valentina.casalone@ircc.it
0119933422 ext. +39

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion